CN102333779B - 苯并吡喃和苯并氧杂*pi3k抑制剂化合物和使用方法 - Google Patents

苯并吡喃和苯并氧杂*pi3k抑制剂化合物和使用方法 Download PDF

Info

Publication number
CN102333779B
CN102333779B CN200980120112.8A CN200980120112A CN102333779B CN 102333779 B CN102333779 B CN 102333779B CN 200980120112 A CN200980120112 A CN 200980120112A CN 102333779 B CN102333779 B CN 102333779B
Authority
CN
China
Prior art keywords
thieno
oxa
dihydrobenzo
cancer
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980120112.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102333779A (zh
Inventor
朱炳炎
P·戈德史密施
T·贝利斯
A·福克斯
N·佩格
S·多
R·戈德史密斯
T·赫夫龙
A·科勒斯尼科夫
S·斯塔本
A·G·埃罗
M·肖
D·P·苏特林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Publication of CN102333779A publication Critical patent/CN102333779A/zh
Application granted granted Critical
Publication of CN102333779B publication Critical patent/CN102333779B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200980120112.8A 2008-03-31 2009-03-30 苯并吡喃和苯并氧杂*pi3k抑制剂化合物和使用方法 Active CN102333779B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4082708P 2008-03-31 2008-03-31
US61/040827 2008-03-31
US10222008P 2008-10-02 2008-10-02
US61/102220 2008-10-02
PCT/US2009/038795 WO2009123971A1 (en) 2008-03-31 2009-03-30 Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use

Publications (2)

Publication Number Publication Date
CN102333779A CN102333779A (zh) 2012-01-25
CN102333779B true CN102333779B (zh) 2015-12-09

Family

ID=40790991

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980120112.8A Active CN102333779B (zh) 2008-03-31 2009-03-30 苯并吡喃和苯并氧杂*pi3k抑制剂化合物和使用方法

Country Status (21)

Country Link
US (4) US7928248B2 (https=)
EP (1) EP2276767B1 (https=)
JP (1) JP5511786B2 (https=)
KR (1) KR101626996B1 (https=)
CN (1) CN102333779B (https=)
AR (1) AR071112A1 (https=)
AU (1) AU2009231885B2 (https=)
BR (1) BRPI0910346A2 (https=)
CA (1) CA2719032C (https=)
CL (1) CL2009000780A1 (https=)
DK (1) DK2276767T3 (https=)
ES (1) ES2480994T3 (https=)
IL (1) IL208359A (https=)
MX (1) MX2010010659A (https=)
PE (1) PE20091720A1 (https=)
PL (1) PL2276767T3 (https=)
RU (1) RU2506267C2 (https=)
SI (1) SI2276767T1 (https=)
TW (1) TWI443102B (https=)
WO (1) WO2009123971A1 (https=)
ZA (1) ZA201007218B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
WO2010090716A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
MX2012000178A (es) * 2009-07-02 2012-02-28 Novartis Ag 2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k.
ES2558742T3 (es) 2009-09-28 2016-02-08 F. Hoffmann-La Roche Ag Compuestos inhibidores de PI3K de benzoxepina y métodos de uso
ES2570569T3 (es) * 2009-09-28 2016-05-19 Hoffmann La Roche Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
JP5728487B2 (ja) * 2009-10-29 2015-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 三環式ヘテロ環化合物
PH12012500901A1 (en) 2009-11-05 2016-08-05 Rhizen Pharmaceuticals Sa Novel benzopyran kinase modulators
KR20130049766A (ko) * 2009-11-13 2013-05-14 메르크 세로노 에스. 에이. 트리사이클릭 피라졸 아민 유도체
US9072783B2 (en) 2009-11-18 2015-07-07 Aridis Pharmaceuticals Highly dispersible powders, compositions and methods for preparation
MX2013001660A (es) 2010-08-11 2013-06-03 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
WO2012126901A1 (en) * 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
HRP20190128T1 (hr) 2011-05-04 2019-03-08 Rhizen Pharmaceuticals S.A. Novi spojevi kao modulatori protein kinaza
HUE043221T2 (hu) 2011-05-27 2019-08-28 Lexicon Pharmaceuticals Inc Notum pektinacetilészteráz 4H-tieno[3,2-C]kromén-alapú inhibitorai és alkalmazási eljárásaik
JP2015507001A (ja) * 2012-02-17 2015-03-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三環式化合物及びその使用方法
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6301316B2 (ja) 2012-05-23 2018-03-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 内胚葉細胞および肝実質細胞の組成物ならびにそれらの細胞を入手および使用する方法
CN109970742A (zh) 2012-07-04 2019-07-05 理森制药股份公司 选择性PI3Kδ抑制剂
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
JP6363120B2 (ja) 2013-03-13 2018-07-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピン化合物の作製方法
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HRP20192041T1 (hr) 2014-12-11 2020-02-07 Natco Pharma Limited [derivati 7-(morfolinil)-2-(n-piperazinil) metil tieno [2, 3-c]piridina kao lijekovi protiv raka]
AU2016242473B2 (en) 2015-03-30 2020-06-25 Jubilant Biosys Limited Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
ES2859478T3 (es) 2016-09-02 2021-10-04 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos sustituidos
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2019018584A1 (en) 2017-07-18 2019-01-24 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
EP3654982A4 (en) 2017-07-18 2021-04-14 Nuvation Bio Inc. 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Oxime ether compounds
CN107805255B (zh) * 2017-09-22 2020-06-16 中国药科大学 呋喃[3，2-b]吡啶-2(1H)-酮类化合物、制备方法和医药用途
JP2021515767A (ja) 2018-03-07 2021-06-24 バイエル・アクチエンゲゼルシヤフト Ｅｒｋ５阻害剤の同定及び使用
CN110467629B (zh) * 2018-05-09 2022-04-08 上海迪诺医药科技有限公司 苯醌衍生物、其药物组合物及应用
EP3911324A4 (en) 2019-01-18 2022-08-17 Nuvation Bio Inc. 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
EP3911323A4 (en) 2019-01-18 2022-11-16 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
CN114156414B (zh) * 2021-11-30 2024-05-31 合肥工业大学 一种高效稳定CsPbI3无机钙钛矿电池的制备方法
CN117209457B (zh) * 2022-06-09 2025-08-15 四川师范大学 一种α-手性脒化合物的合成
CN115403591A (zh) * 2022-10-08 2022-11-29 河南师范大学 一种合成萘并噻吩并奥塞平并异喹啉酮类化合物的方法
WO2025082467A1 (zh) * 2023-10-19 2025-04-24 成都先导药物开发股份有限公司 一种免疫调节剂
CN117736200A (zh) * 2023-12-18 2024-03-22 西安交通大学 2-[(6H-二苯并[b,d]吡喃-3-基)氧]酰胺类衍生物及其制备方法和应用
CN117736199A (zh) * 2023-12-18 2024-03-22 西安交通大学 一种3位含氧基取代的6H-二苯并[b,d]吡喃类衍生物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101039667A (zh) * 2004-10-15 2007-09-19 辉瑞大药厂 双相性精神障碍和相关症状的治疗
CN101048418A (zh) * 2004-10-07 2007-10-03 贝林格尔·英格海姆国际有限公司 Pi3－激酶
WO2008019139A2 (en) * 2006-08-04 2008-02-14 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
WO2008039520A2 (en) * 2006-09-26 2008-04-03 Synta Pharmaceuticals Corp. Fused ring compounds for inflammation and immune-related uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504702D0 (en) 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
WO1994014777A1 (en) 1992-12-28 1994-07-07 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
US5985799A (en) 1995-11-17 1999-11-16 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
DE19831878C2 (de) * 1998-07-17 2001-05-17 Aventis Pharma Gmbh Polycyclische Thiazolidin-2-yliden Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19908537A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908535A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908538A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908533A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
EP1403256A4 (en) * 2001-06-05 2004-10-20 Fujisawa Pharmaceutical Co FUSED IMIDAZOLE DERIVATIVE
EP1530565A1 (en) 2002-07-19 2005-05-18 Pharmacia Corporation Substituted thiophene carboxamide compounds for the treatment of inflammation
WO2004069245A1 (en) 2003-02-07 2004-08-19 Warner-Lambert Company Llc Oxazolidinone derivates n-substituted by a tricyclic ring, for use as antibacterial agents
RU2281947C1 (ru) * 2005-07-05 2006-08-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные карбамоилазагетероциклы, фокусированная библиотека, фармацевтическая композиция и способ получения
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101048418A (zh) * 2004-10-07 2007-10-03 贝林格尔·英格海姆国际有限公司 Pi3－激酶
CN101039667A (zh) * 2004-10-15 2007-09-19 辉瑞大药厂 双相性精神障碍和相关症状的治疗
WO2008019139A2 (en) * 2006-08-04 2008-02-14 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
WO2008039520A2 (en) * 2006-09-26 2008-04-03 Synta Pharmaceuticals Corp. Fused ring compounds for inflammation and immune-related uses

Also Published As

Publication number Publication date
AU2009231885B2 (en) 2014-04-03
US8399690B2 (en) 2013-03-19
US20090247567A1 (en) 2009-10-01
ZA201007218B (en) 2012-06-27
US9309265B2 (en) 2016-04-12
JP2011517457A (ja) 2011-06-09
WO2009123971A1 (en) 2009-10-08
CA2719032C (en) 2016-11-08
EP2276767B1 (en) 2014-05-07
IL208359A (en) 2016-07-31
AU2009231885A1 (en) 2009-10-08
CA2719032A1 (en) 2009-10-08
RU2506267C2 (ru) 2014-02-10
TW200944531A (en) 2009-11-01
SI2276767T1 (sl) 2014-08-29
US20130123263A1 (en) 2013-05-16
US20110130363A1 (en) 2011-06-02
MX2010010659A (es) 2010-10-26
CN102333779A (zh) 2012-01-25
DK2276767T3 (da) 2014-07-14
KR101626996B1 (ko) 2016-06-02
RU2010143319A (ru) 2012-05-10
HK1147741A1 (en) 2011-08-19
JP5511786B2 (ja) 2014-06-04
EP2276767A1 (en) 2011-01-26
IL208359A0 (en) 2010-12-30
PE20091720A1 (es) 2009-11-26
US8846762B2 (en) 2014-09-30
AR071112A1 (es) 2010-05-26
PL2276767T3 (pl) 2014-09-30
CL2009000780A1 (es) 2010-01-15
BRPI0910346A2 (pt) 2015-10-06
US20140336154A1 (en) 2014-11-13
ES2480994T3 (es) 2014-07-29
KR20100137551A (ko) 2010-12-30
TWI443102B (zh) 2014-07-01
US7928248B2 (en) 2011-04-19

Similar Documents

Publication Publication Date Title
CN102333779B (zh) 苯并吡喃和苯并氧杂*pi3k抑制剂化合物和使用方法
RU2557658C2 (ru) Бензоксепиновые ингибиторы pi3 и способы применения
JP5608099B2 (ja) ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
HK1147741B (en) Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
AU2013221987A1 (en) Benzoxepin P13K inhibitor compounds and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant